Anticoagulation Therapy for Pulmonary Embolism

Initial Treatment and Maintenance

• The American College of Chest Physicians recommends transitioning to 20 mg once daily with food after 21 days of initial treatment for patients with pulmonary embolism 1
• The maintenance dose should be continued for a minimum of 3 months, according to the Chest guidelines, for patients with pulmonary embolism 2
• Direct oral anticoagulants (DOACs) like rivaroxaban are recommended over vitamin K antagonists for treatment-phase anticoagulant therapy, according to the American College of Chest Physicians, with high-quality evidence 2, 3, 4, 5, 6
• Rivaroxaban must be taken with food to ensure optimal absorption, with the American College of Cardiology recommending this to increase bioavailability, for patients with deep vein thrombosis (DVT) and Factor V Leiden 3

Extended Anticoagulation

• For patients with transient risk factors that have resolved, 3 months of treatment may be sufficient, as suggested by the European Heart Journal and Chest guidelines, for patients with pulmonary embolism 2, 7
• The Chest guidelines recommend considering transitioning to prophylactic dosing of 10 mg once daily after completing 6-12 months of standard therapy, for patients with unprovoked pulmonary embolism or persistent risk factors 2
• The European Heart Journal guidelines specifically recommend a reduced-dose regimen of 10 mg once daily for extended therapy to prevent recurrence, for patients with pulmonary embolism 7
• Extended treatment after completing 6-12 months of standard therapy can be done with 20 mg once daily for continued full-dose therapy or 10 mg once daily for reduced-dose extended therapy, preferred for long-term prevention, according to the American College of Chest Physicians, for patients with unprovoked DVT or persistent risk factors 8

Special Patient Populations

• Patients with unprovoked pulmonary embolism or pulmonary embolism associated with persistent risk factors may require extended anticoagulation, according to the Chest and European Heart Journal guidelines, with moderate-quality evidence 2, 7
• The European Heart Journal guidelines recommend that patients with antiphospholipid antibody syndrome should remain on vitamin K antagonists rather than rivaroxaban, due to increased risk of thrombosis 7
• Rivaroxaban is contraindicated in patients with severe renal impairment (CrCl <15 mL/min), hepatic disease associated with coagulopathy, Child-Pugh B and C liver cirrhosis, or liver enzymes greater than 2 times the upper limit of normal with coagulopathy, according to the European Heart Journal guidelines, with high-quality evidence 4, 9, 10
• Patients with high risk of bleeding (HAS-BLED ≥3) should consider rivaroxaban 15 mg once daily instead of 20 mg, particularly during concomitant antiplatelet therapy, as per the European Heart Journal guidelines, with moderate-quality evidence 11

Monitoring and Reevaluation

• Patients on extended anticoagulation should have their treatment reevaluated at least annually, as recommended by the Chest guidelines, to assess the risk of recurrence and bleeding 2
• Regular assessment of drug tolerance, adherence, hepatic and renal function, and bleeding risk is essential, according to the European Heart Journal guidelines, with high-quality evidence 7
• Baseline testing should include CBC, renal and hepatic function panel, aPTT, and PT/INR before initiating rivaroxaban therapy, as per clinical guidelines, to assess the risk of bleeding and thrombosis 12
• Follow-up testing should include hemoglobin, hematocrit, and platelet count at least every 2-3 days for the first 14 days and every 2 weeks thereafter, to monitor for signs of bleeding or thrombosis 12
• Standard PT/INR monitoring is not appropriate for monitoring rivaroxaban effect, and no routine coagulation monitoring is required, but specific anti-Factor Xa assays with rivaroxaban calibration may be used if needed, according to the European Heart Journal guidelines, with high-quality evidence 4

Dosing and Administration

• The following table summarizes the dosing recommendations for rivaroxaban:

• Dose adjustments are recommended for patients with renal impairment, with a dose of 15 mg once daily with food if the creatinine clearance is between 15-49 mL/min, and 15 mg once daily for severe renal impairment (CrCl 15-29 mL/min), according to the European Heart Journal guidelines, with high-quality evidence 4, 9

Contraindications and Precautions

• Rivaroxaban is contraindicated in patients with mechanical heart valves, according to the European Heart Journal guidelines, with high-quality evidence 11
• Patients with heparin-induced thrombocytopenia can be treated with rivaroxaban at 15 mg twice daily until platelet recovery, then 20 mg once daily, according to the American College of Chest Physicians, with moderate-quality evidence 13
• For procedures with low risk of bleeding, rivaroxaban should be suspended 24 hours before, and for procedures with high risk of bleeding, it should be suspended 48 hours before, considering the shorter half-life in younger patients, as recommended by Blood advances, with high-quality evidence 14

Bleeding Risk and Reversal

• The risk of intracranial bleeding is lower with rivaroxaban compared to warfarin, but the risk of gastrointestinal bleeding may be increased, with major bleeding significantly lower with rivaroxaban (1.1% vs 2.2%) in the EINSTEIN PE trial, according to the European Heart Journal guidelines, with high-quality evidence 4
• Rivaroxaban restores therapeutic anticoagulation within 3 hours of administration, unlike warfarin which takes days, according to the American College of Chest Physicians, with high-quality evidence 10
• Reversal of rivaroxaban's effect can be done with prothrombin complex concentrate for severe bleeding, and tranexamic acid may be considered, although evidence is limited, according to the European Heart Journal guidelines, with low-quality evidence 10